Open access · US-GOV via ClinicalTrials.gov Clinical trial

Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories

Authors not listed

Sapere Bio · 2022

Loss of proteostasis Human Randomized controlled trial

Abstract

This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-31 MST

Cite this

APA

Anonymous. (2022). Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories. <em>Sapere Bio</em>. https://clinicaltrials.gov/study/NCT04932031

Vancouver

Anonymous. Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories. Sapere Bio. 2022.

BibTeX

@misc{anon2022System, title = {Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories}, author = {Anonymous}, journal = {Sapere Bio}, year = {2022}, }